
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with ...
Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with …